Pediatric hereditary angioedema: an update

Hereditary angioedema (HAE) with C1-inhibitor (C1-Inh) deficiency (C1-Inh-HAE) is a rare, life-threatening, and disabling genetic disorder characterized by self-limited tissue swelling caused by deficiency or dysfunction of C1-Inh. Our aim in this update is to discuss new advances in HAE therapy, fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabharwal, Geetika, Craig, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531155/
https://www.ncbi.nlm.nih.gov/pubmed/28781749
http://dx.doi.org/10.12688/f1000research.11320.1
_version_ 1783253345441415168
author Sabharwal, Geetika
Craig, Timothy
author_facet Sabharwal, Geetika
Craig, Timothy
author_sort Sabharwal, Geetika
collection PubMed
description Hereditary angioedema (HAE) with C1-inhibitor (C1-Inh) deficiency (C1-Inh-HAE) is a rare, life-threatening, and disabling genetic disorder characterized by self-limited tissue swelling caused by deficiency or dysfunction of C1-Inh. Our aim in this update is to discuss new advances in HAE therapy, focusing mainly on the various treatment options that have become available recently and also drugs that are under trial for prophylaxis to prevent attacks. There is a paradigm shift to where the treatment of HAE is headed, focusing now on prophylactic treatment rather than abortive management.
format Online
Article
Text
id pubmed-5531155
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-55311552017-08-04 Pediatric hereditary angioedema: an update Sabharwal, Geetika Craig, Timothy F1000Res Review Hereditary angioedema (HAE) with C1-inhibitor (C1-Inh) deficiency (C1-Inh-HAE) is a rare, life-threatening, and disabling genetic disorder characterized by self-limited tissue swelling caused by deficiency or dysfunction of C1-Inh. Our aim in this update is to discuss new advances in HAE therapy, focusing mainly on the various treatment options that have become available recently and also drugs that are under trial for prophylaxis to prevent attacks. There is a paradigm shift to where the treatment of HAE is headed, focusing now on prophylactic treatment rather than abortive management. F1000Research 2017-07-24 /pmc/articles/PMC5531155/ /pubmed/28781749 http://dx.doi.org/10.12688/f1000research.11320.1 Text en Copyright: © 2017 Sabharwal G and Craig T http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Sabharwal, Geetika
Craig, Timothy
Pediatric hereditary angioedema: an update
title Pediatric hereditary angioedema: an update
title_full Pediatric hereditary angioedema: an update
title_fullStr Pediatric hereditary angioedema: an update
title_full_unstemmed Pediatric hereditary angioedema: an update
title_short Pediatric hereditary angioedema: an update
title_sort pediatric hereditary angioedema: an update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531155/
https://www.ncbi.nlm.nih.gov/pubmed/28781749
http://dx.doi.org/10.12688/f1000research.11320.1
work_keys_str_mv AT sabharwalgeetika pediatrichereditaryangioedemaanupdate
AT craigtimothy pediatrichereditaryangioedemaanupdate

Ejemplares similares